GC376 sodium

TargetMol
Product Code: TAR-T5188
Supplier: TargetMol
CodeSizePrice
TAR-T5188-5mg5mg£144.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5188-1mL1 mL * 10 mM (in DMSO)£161.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5188-10mg10mg£178.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5188-25mg25mg£219.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5188-50mg50mg£302.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T5188-100mg100mg£418.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
GC376 is an inhibitor of 3C-like proteases (3CLpro) with IC50 values range from 0.49~4.35 μM.
CAS:
1416992-39-6
Formula:
C21H30N3NaO8S
Molecular Weight:
507.53
Pathway:
Microbiology/Virology
Purity:
0.9656
SMILES:
[Na+].CC(C)CC(NC(=O)OCc1ccccc1)C(=O)NC(CC1CCNC1=O)C(O)S([O-])(=O)=O
Target:
SARS-CoV

References

Kim Y, et al. Broad-spectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses. J Virol. 2012 Nov;86(21):11754-62. Mohseni N, Royster A, Ren S, et al.A novel compound targets the feline infectious peritonitis virus nucleocapsid protein and inhibits viral replication in cell culture.Journal of Biological Chemistry.2023: 102976. Theerawatanasirikul S, Kuo C J, Phecharat N, et al. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses[J]. Antiviral research,. 2020, 182: 104927. Theerawatanasirikul S, Kuo C J, Phecharat N, et al. Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses. Antiviral research, 2020, 182: 104927. Pedersen NC, et al. Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis. J Feline Med Surg. 2018 Apr;20(4):378-392. Wang Y C, Yang W H, Yang C S, et al. Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug[J]. American Journal of Cancer Research. 2020, 10(8): 2535. Bai Y, Ye F, Feng Y, et al. Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir. Signal Transduction and Targeted Therapy. 2021, 6(1): 1-3 Ye X, Li Y, Guo L, et al.Synthesis and enzymatic inhibition effects of thiazolidinedione 3C-like protease inhibitors.Journal of Chemical Research.2023, 47(1): 17475198231152556. Hahn F, Wangen C, H?ge S, et al.The Trimeric Artesunate Analog TF27, a Broadly Acting Anti-Infective Model Drug, Exerts Pronounced Anti-SARS-CoV-2 Activity Spanning Variants and Host Cell Types.Pharmaceutics.2022, 15(1): 115. Fu L, Ye F, Feng Y, et al. Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nature communications. 2020, 11(1): 1-8. Herrmann A, Jungnickl D, Cordsmeier A, et al. Cloning of a Passage-Free SARS-CoV-2 Genome and Mutagenesis Using Red Recombination. International Journal of Molecular Sciences. 2021, 22(19): 10188. Fu L, Ye F, Feng Y, et al Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease. Nature communications. 2020 Sep 4;11(1):4417. doi: 10.1038/s41467-020-18233-x. Chen Y, Li X, Wang M, et al.A cysteine protease inhibitor GC376 displays potent antiviral activity against coxsackievirus infection.Current Research in Microbial Sciences.2023: 100203. Wang Y C, Yang W H, Yang C S, et al. Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug. American Journal of Cancer Research. 2020, 10(8): 2535